Sarcoma
Conditions
Keywords
localized osteosarcoma, stage II adult soft tissue sarcoma, stage III adult soft tissue sarcoma
Brief summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with ifosfamide may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects of giving sorafenib together with ifosfamide and to see how well it works in treating patients with high-grade soft tissue sarcoma or bone sarcoma that can be removed by surgery.
Detailed description
OBJECTIVES: Primary * Assess the safety, toxicity, and efficacy of neoadjuvant sorafenib tosylate and ifosfamide in patients with resectable high-grade soft tissue or bone sarcoma. Secondary * Assess the long-term efficacy or impact of therapy in these patients, in terms of the duration of local recurrence-free survival, distant recurrence-free survival, and disease-specific survival. OUTLINE: * Neoadjuvant therapy: Patients receive oral sorafenib tosylate twice daily on days 1-14 in course 1. Patients then receive oral sorafenib tosylate twice daily on days 1-28 and ifosfamide IV continuously on days 1-7 in courses 2 and 3. Treatment repeats every 14-28 days\* for 3 courses. NOTE: \*Course 1 is 14 days in duration; courses 2 and 3 are 28 days in duration. * Surgery: At least 1 week after the completion of neoadjuvant therapy, patients undergo surgery. * Adjuvant therapy: Beginning ≥ 3 weeks after surgery, patients who respond to neoadjuvant therapy receive oral sorafenib twice daily for 6 months. Patients also receive 2 courses of ifosfamide as in courses 2 and 3 of neoadjuvant therapy.
Interventions
DRUGsorafenib
Patients with sarcoma who have resectable disease will be treated with neoadjuvant sorafenib and ifosfamide. PET/CT will be used to assess the metabolic and radiographic response to therapy.
DRUGIfosfamide
Patients with sarcoma who have resectable disease will be treated with neoadjuvant ifosfamide and sorafenib. PET/CT will be used to assess the metabolic and radiographic response to therapy.
Sponsors
Jonsson Comprehensive Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathologically confirmed high grade sarcoma of the soft tissue or bone * participants Identified as a proper candidate for ifosfamide-based neoadjuvant therapy * candidates must have operable disease for which a resection is planned * ECOG performance status 0-1 * Hemoglobin ≥ 9.0 g/dL * ANC ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Total bilirubin ≤ 1.5 times upper limit of normal (ULN) * ALT and AST ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver involvement) * INR \< 1.5 or PT/PTT normal.Concurrent anticoagulation therapy with warfarin or heparin allowed * Creatinine ≤ 1.5 times ULN * women of childbearing potential must have negative pregnancy test performed within 7 days prior to start of treatment. * Fertile patients must use effective contraception during and for ≥ 2 weeks after completion of study therapy. * A signed informed consent must be obtained prior to any study specific procedures.
Exclusion criteria
* known HIV infection * chronic hepatitis B or C infection * clinically active serious infection \> CTCAE grade 2 * NYHA class III or IV congestive heart failure * unstable angina (i.e., anginal symptoms at rest) or new onset angina within the past 3 months * myocardial infarction within the past 6 months * cardiac ventricular arrhythmias requiring anti-arrhythmic therapy * uncontrolled hypertension (i.e., systolic blood pressure \[BP\] \> 150 mm Hg or diastolic BP \> 90 mm Hg) despite optimal medical management * thrombolic or embolic events (e.g., cerebrovascular accident, including transient ischemic attacks) within the past 6 months * pulmonary hemorrhage or bleeding event ≥ CTCAE grade 2 within the past 4 weeks * other hemorrhage or bleeding event ≥ CTCAE grade 3 within the past 4 weeks * Any condition that would impair the ability to swallow whole pills * malabsorption problem * Any known severe hypersensitivity to sorafenib tosylate or any of its excipients * known or suspected allergy to sorafenib tosylate or any agent given in this study * serious nonhealing wound, ulcer, or bone fracture * evidence or history of bleeding diathesis or coagulopathy * significant traumatic injury within the past 4 weeks * major surgery or open biopsy within 4 weeks of starting treatment * Concomitant St. John's wort or rifampin * KNown brain metastases. Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastases. * any condition that impairs patients' ability to swallow pills * any malabsorption problem
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Using PET/CT Scan to Measure Safety, Toxicity, and Efficacy of Neoadjuvant Sorafenib Tosylate and Ifosfamide in Patients With Resectable High-grade Soft Tissue or Bone Sarcoma. | Participants were followed for duration of study, an average of 1 year. | After cycle 1, a limited PET/CT scan of the affected site will be performed to assess response to sorafenib treatment alone. After cycle 3, prior to surgery, a limited PET/CT scan of the affected site will be performed to assess response to the combination sorafenib and ifosfamide treatment. |
Secondary
| Measure | Time frame |
|---|---|
| Local and Distant Recurrence-free Survival | conclusion of study |
Countries
United States
Participant flow
Recruitment details
Dates of recruitment period: 08/20/2008 - 07/19/2010 Types of location: Academic medical clinics
Pre-assignment details
There are no pre-assignment details to describe
Participants by arm
| Arm | Count |
|---|---|
| Sorafenib + Ifosfamide | 7 |
| Total | 7 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| REP: Surgical Resection | progressive disease | 1 |
| Treatment Period (Sorafenib+Ifosfamide) | Adverse Event | 1 |
| Treatment Period (Sorafenib+Ifosfamide) | disease progression | 2 |
Baseline characteristics
| Characteristic | Sorafenib + Ifosfamide |
|---|---|
| Age, Continuous | 56 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 7 Participants |
| Sex: Female, Male Female | 2 Participants |
| Sex: Female, Male Male | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 7 / 7 |
| serious Total, serious adverse events | 4 / 7 |
Outcome results
Primary
Using PET/CT Scan to Measure Safety, Toxicity, and Efficacy of Neoadjuvant Sorafenib Tosylate and Ifosfamide in Patients With Resectable High-grade Soft Tissue or Bone Sarcoma.
After cycle 1, a limited PET/CT scan of the affected site will be performed to assess response to sorafenib treatment alone. After cycle 3, prior to surgery, a limited PET/CT scan of the affected site will be performed to assess response to the combination sorafenib and ifosfamide treatment.
Time frame: Participants were followed for duration of study, an average of 1 year.
Population: Due to the study closing early and the few number of participants enrolled, the outcome measures were not done.
Secondary
Local and Distant Recurrence-free Survival
Time frame: conclusion of study
Population: Due to study closing early and the few number of participants enrolled, the outcome measures were not done.